Liron Carmel sold $1,100 of PLRZ
director at Polyrizon Ltd.. 100 shares at an average of $11.00, traded Mar 30, 2026, filed Mar 31, 2026.
Score components
- +15RoleDirector
- 0Trade size$1k at market
- 0Share of holdings soldSold 2.4% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +36.1%, 3m +7.2%, 6m -10.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-26-037467, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | SOpen-market sale Ordinary Shares | -100 | $11.00 | $1,100 | 4,069 | Mar 31, 2026 |
Related signals
Other insiders at Polyrizon Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | Polyrizon Ltd. | Oz Adler director | $40k 3,292 shares | -14% | |
| 35Weak | Polyrizon Ltd. | Liron Carmel director | $12k 942 shares | -23% | |
| 40Moderate | Polyrizon Ltd. | Tomer Izraeli Chief Executive Officer | $5,925 500 shares | -2% | |
| 51Moderate | Polyrizon Ltd. | Tomer Izraeli Chief Executive Officer | $43k 3,900 shares | -11% | |
| 40Moderate | Polyrizon Ltd. | Tidhar Turgeman Chief Technology Officer | $32k 2,917 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.